De-ESCALaTE HPV

Background

Phase III open-label non-inferiority RCT (De-ESCALaTE HPV). N=334, p16-positive low-risk HPV+ oropharyngeal SCC (T1–T3, N0–N2c, M0), 32 UK/Irish/Dutch centers, 2012–2016. Low-risk = non-smoker or ≤10 pack-years. Hypothesis: cetuximab reduces severe (grade ≥3) toxicity while preserving efficacy vs cisplatin.

Interventions and follow up

Arm A: Cetuximab (400 mg/m² loading, then 250 mg/m²/wk × 7 wk) + IMRT (70 Gy/35 fx)
Arm B: Cisplatin (100 mg/m² D1, D22, D43) + IMRT (70 Gy/35 fx)
Primary endpoint: Severe (grade ≥3) toxicity at 24 months (non-inferiority)
mFollow up: 28.5 month

Results

Grade ≥3 toxicity at 24 months: 64.0% (cetuximab) vs 64.1% (cisplatin) — equivalent, non-inferiority met
2-year OS: 89.4% vs 97.5%, HR 5.0 (95% CI 1.7–14.7), P=.001 — significantly WORSE with cetuximab
2-year recurrence rate: 16.1% vs 6.0%, P=.0007

Adverse events

Overall grade ≥3: ~64% in both arms (different profiles)
Cisplatin: more nausea/vomiting, nephrotoxicity, ototoxicity
Cetuximab: more grade 3 acneiform rash (24%), mucositis
Net: neither arm with aggregate toxicity advantage

Conclusions

Cetuximab did not reduce severe toxicity vs cisplatin (equivalence met) but was significantly inferior for OS and tumor control. Cisplatin remains the standard concurrent agent in HPV+ OPC and cannot safely be replaced by cetuximab even in low-risk patients.

Key Limitations

Smaller sample than RTOG 1016; only low-risk HPV+ (non-smokers) enrolled, limiting generalizability. Non-inferiority toxicity design met, but OS finding overrides it. Published concurrently with RTOG 1016 (same Lancet issue) — identical message.

Clinical Context

With RTOG 1016, definitively established cetuximab should not replace cisplatin in HPV+ OPC — even in low-risk patients, substitution incurs a survival cost. Current de-escalation strategies focus on reducing radiation dose (e.g., 60 Gy vs 70 Gy) rather than substituting systemic agents.

References